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ABSTRACT 
Objective: Although jaundice is a common condition of the newborn, it rarely reaches levels 
that require intervention. Despite this, frequent assessments of serum bilirubin levels are 
made causing unnecessary trauma to the infant and family and avoidable costs to the facility. 
The objective of the present study was to assess whether cephalocaudal progression of 
jaundice (measured by Kramer’s scale) could be useful as measure to detect which infants in a 
well baby nursery require testing.  
Methods: Four hundred and five infants admitted to postnatal wards at a large teaching 
Hospital in Brisbane were assessed for jaundice using Kramer's scale. Levels of jaundice were 
compared using the total serum bilirubin level as the reference standard. The scale was 
assessed using sensitivity, specificity, positive and negative predictive values.  
Results: There was a low level of agreement between jaundice predicted by Kramer’s scale 
and the reference standard. At < 48 hours the sensitivity was 67% and specificity was 48%. 
The positive and negative predictive values were 4% and 98% respectively. Between 49 and 
72 hours the sensitivity was 89% and specificity was 54% with a positive predictive value 
10% and a negative predictive value 99%. Of the 111 infants who had blood drawn for 
testing, who were over 72 hours of age, none required phototherapy.  
Conclusion: Using Kramer’s scale to assess which infants require intervention for jaundice 
leads to over servicing. If the number of unnecessary tests is to be reduced, more accurate 
methods for identifying infants who may be at risk for hyperbilirubinaemia must be used. 
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INTRODUCTION 
Neonatal jaundice affects approximately 60 percent of full-term infants and almost every 
premature infant.1 For the vast majority of these newborns increased total serum bilirubin 
(TSB) levels are benign and transitory2 with only 5% reaching levels that require treatment.3  
Extreme hyperbilirubinaemia is a relatively rare occurrence with 0.42 percent of infants who 
undergo testing having TSB levels above 342 μmol/L.4-5 Despite this, between 17 - 52% of 
infants have blood taken for bilirubin testing.5 Jaundice meters have been developed and 
refined to more effectively target those who may require treatment 6-9 and, although they seem 
to be cost effective10 their use is not widespread.  
The decision for laboratory testing rests with those caring for the infant, generally the 
midwife, and is generally based on clinical observation. This is certainly the case in our 
hospital but we have no policy for ordering such tests. In 1998, a six-month review of our 
request patterns indicated that approximately 78% of TSB level tests were ordered 
unnecessarily. That is, results did not reach levels at which phototherapy should ‘be 
considered’ or ‘be required’ as defined by the American Academy of Pediatrics guidelines.11 
These guidelines assess the need for interventions (such as phototherapy or transfusion) by 
considering the TSB level in relation to the infant’s age. The guideline is a widely used 
reference or ‘gold standard’ when making decisions about interventions for neonatal jaundice.  
One simple approach that has been used elsewhere to determine the need for serum 
bilirubin testing is the progression of yellow discolouration of the skin from the head to the 
feet or cephalocaudal progression using the Kramer’s scale12. The scale is based on a 1969 
study of 108 full term infants which found that bilirubin concentrations were correlated to 5 
specific ‘dermal zones’ (i) head and neck, (ii) upper trunk, (iii) lower trunk and thighs, (iv) 
arms and legs below the knees, (v) hands and feet. Lowest TSB levels were associated with 
yellow discoloration of the head and neck only and highest levels where the discolouration 
extended to the hands and feet. 
The primary aim of this study was to assess if the Kramer’s scale could be used as a screening 
instrument to determine which infants require TSB level testing in a well baby nursery.  
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METHODS 
Sample: 
The study was conducted at a large metropolitan teaching hospital in Brisbane, 
Australia where approximately 5,000 infants are born each year. A convenience sample of 
otherwise healthy infants who were 38 weeks or over, for whom a request for a TSB level 
was made, were included in the study. Neonates who were admitted to the neonatal intensive 
care unit or special care unit were excluded. 
Procedure: 
Before commencing the investigation midwives on the postnatal wards received education 
about the study including the use of the Kramer’s scale, a visual assessment tool to identify 
levels of jaundice (see Fig 1). When a TSB level test was ordered, information including 
demographic details, method of delivery and infant feeding method was collected. To assess 
the level of jaundice the infant's skin was blanched using thumb pressure and the colour of the 
underlying skin noted. Observations were taken under florescent lighting augmented by 
natural lighting during daylight hours or under florescent lighting alone depending on when 
the test was ordered.  While this meant that visual assessments of the infants were made under 
varying circumstances it reflects the reality of clinical practice. A trained phlebotomist took 
all blood tests. Results of the bilirubin test were obtained from the Hospital's on-line result 
service. Ethics approval for the study was not required as there were no intervention outside 
normal care. 
 
Statistical analysis: 
Statistical analysis was carried out using SPSS for Windows, version 12.01 (SPSS Inc. 
Chicago 2003). Standard descriptive statistics were calculated for all variables. Differences 
between proportions were compared using the χ2 test with Yate's correction or two-tailed 
Fisher's exact test if appropriate. One-way analysis of variance was used to examine the 
relationships between categorical and continuous variables. To determine the usefulness of 
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the Kramer's scale as a screening test, we dichotomised the dermal zones 1 and 2 (head and 
neck and trunk) into one group the remaining 3 zones into the second group and calculated 
the sensitivity (how good the screening test is in detecting those who have the condition), 
specificity (how good the screening test is in detecting those who do not have the condition), 
positive predictive value (the probability of actually having the condition given that the 
screening test is positive), and the negative predictive value (the probability of not having the 
condition given that the screening test is negative). The reference standard was the total serum 
bilirubin level and we used the American Academy of Pediatrics guidelines to define the 
point at which phototherapy might be considered or recommended.11 We calculated Statistical 
significance was defined as a P-value of < 0.05. 
 
Results 
A total of 405 otherwise healthy term newborns were enrolled in the study. The average age 
at which a TSB test was taken was 67 hours with a range of 5 to 243 hours. Statistically 
higher TSB levels were found in infants delivered by forceps compared with other modes of 
delivery (p = < 0.04). Cephalhaematoma was recorded for 16 (4%) infants (six spontaneous 
vaginal delivery, seven vacuum extraction, and three Caesarean section) and these infants 
were more likely to have a higher TSB levels than those infants who did not have a 
cephalhaematoma (p = < 0.03). Infants who had a caput succedaneum (n=10) also had higher 
TSB levels when compared with infants without a caput succedaneum (p = < 0.03). Eight of 
the 10 infants who developed caput succedaneum were delivered by vacuum extraction. There 
was a non-significant trend towards higher TSB levels among Asian infants but gender, 
feeding method or bruising had no effect on TSB levels (Table 1). A relationship was found 
between the dermal zones of the Kramer’s scale and mean TSB levels (p = > 0.000) but 
confidence intervals were wide (Table 2). When the relationship between the Kramer’s scale 
and TSB levels were controlled by age, phototherapy treatment was justified for 12 (3.3%) 
infants (Table 3) and a further 88 (24.2%) infants had TSB levels that warranted 
consideration for phototherapy (Table 4). When compared with the reference standard, the 
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Kramer’s scale was inneffective as a screening instrument. At < 48 hours the sensitivity was 
67% and specificity was 48%. The positive and negative predictive values were 4% and 98% 
respectively. Between 49 and 72 hours the sensitivity was 89% and specificity was 54% with 
a positive predictive value of 10% and a negative predictive value of 99%. Of the 111 infants 
who had blood drawn for testing, who were over 72 hours of age, none required phototherapy.  
 
Discussion 
Our investigation was based on the well-known observation that jaundice associated with 
newborn infants generally appears first in the head and moves down the torso and finally to 
the soles of the feet and palms of the hands.13 We also incorporated the notion, proposed by 
Kramer in 1969, that there was a relationship between this cephalocaudal progression and 
serum bilirubin levels.13 Kramer found that bilirubin concentrations were correlated to 5 
specific dermal zones although wide ranges of bilirubin levels were noted in each zone. 
Similar correlations have been found in other studies of both full term and preterm infants.14-16 
Our results are in line with these studies and we also found similar wide ranges in TSB levels 
in each of the dermal zones. These wide ranges explain why, even though there was a strong 
overall correlation between the level of jaundice and the 5 zones, the positive predictive value 
remained low.   
 
Although our results were consistent with existing evidence, we were more interested in 
whether or not visual assessment, aided by use of the Kramer’s scale, would assist with more 
precise targeting of infants who may require an intervention for jaundice, such as 
phototherapy. Our results do not support the use of Kramer’s scale for this purpose. Age and 
TSB levels were recorded for 364 of the infants for whom a request for TSB levels had been 
made; only 12 required treatment with phototherapy. These results are not unusual. In one 
recent study only 3 of 164 infants who were assessed following hospital discharge were found 
to have TSB levels at which phototherapy would be considered.17 Similarly, in a hospital-
based cohort of 66 newborns who were assessed by nurses, just one was found to be within 
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treatment range.18 Moyer and colleagues also concluded that decisions made by experienced 
practitioners about the need for serum bilirubin testing was not much better than would be 
predicted by chance.19  
 
Unnecessary testing has considerable financial implications for health services. In our own 
facility the pathology service currently charges the hospital (Aus) $11.40 to collect and 
process blood for an estimate of TSB level. Considering that we order approximately 2,300 
tests each year, costing in excess of (Aus) $26,000, there exists a potential for substantial cost 
savings.  
 
The difficulty lies in understanding why so many needless tests are ordered and what can be 
done about it. Findings from earlier studies, which used cut-off points to assess TSB levels 
provide a useful guide. For example one author found that infants who were not jaundiced 
below the nipple line were unlikely to have bilirubin levels of 205 μmol/L19 and another 
observed that none of the infants who were not visibly jaundiced below the knee had serum 
bilirubin levels greater than 188 μmol/L.14 Apart from these results being somewhat 
contradictory, our larger study found that these levels were exceeded in every zone.  
 
The current American Academy of Pediatrics clinical practice guideline20 continues to 
recommend frequent assessment for jaundice by blanching the skin. The guideline also 
includes some parameters for decisions about laboratory investigation of jaundice after 24 
hours. It suggests that blood should be taken if 'jaundice appears excessive for an infant's age' 
(p300) but this leaves practitioners again with subjective decision making. Our data indicate 
that significant hyperbilirubinaemia is present in very few infants and that more refined 
methods are needed for identifying those who are at greatest risk. A requirement for testing 
some infants is clear; for example where there is clinical jaundice less than 24 hours of age or 
a blood group incompatibility with a positive Coombs' test. Infants who sustain a 
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cephalhaematoma or caput succendaneum also need testing. For other infants transcutaneous 
bilirubinometry may be a practical and cost effective way of supplementing clinical 
observation; other studies suggest that there is a high correlation between bilirubin estimates 
from jaundice meters and TSB levels and that they perform well as a screening tool, to 
identify infants who may require TSB testing.6,7,9 
 
Another approach would be to require that those who order tests are qualified to do so. 
Insisting on a demonstrated understanding of the current American Academy of Pediatrics 
guideline could form the basis for accreditation.  
 
Conclusion 
Our investigation has demonstrated the inadequacies of using the Kramer’s scale to determine 
the need for TSB level testing. If the number of unnecessary tests is to be reduced, more 
accurate methods for identifying infants who may be at risk for hyperbilirubinaemia must be 
found. 
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Figure 1 Dermal zones: 1) head and neck, 
2) upper trunk, 3) lower trunk, thighs,  
4) arms, legs below knee, 5) hands, feet.  
(Kramer 1969,p 455). 
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Table 1 Demographic characteristics, risk factors and relationship to TSB levels   
  
N 
TSB level Mean 
(SD) 
95% Confidence 
interval 
  
Sig 
Gender  
      Male 
      Female  
Type of Delivery  
      Spontaneous vaginal delivery  
      Forceps  
      Ventouse Extraction 
      Caesarean Section 
Feeding Method  
      Breast  
      Formula  
      Breast and formula 
Ethnicity  
      Caucasian  
      Asian 
      Other 
Bruising 
       Yes 
        No 
Cephalhaematoma 
       Yes 
        No 
Caput succendaneum 
        Yes 
        No 
 
230 
171 
 
201 
14 
35 
146 
 
291 
35 
64 
 
300 
50 
43 
 
53 
316 
 
15 
322 
 
10 
320 
 
206.7 (54.4) 
211.5 (56.6) 
 
210.8 (58.6) 
241.6 (51.3) 
215.6 (64.8) 
201.0 (47.5) 
 
211.8 (57.6) 
193.2 (46.9) 
201.6 (47.6) 
 
207.3 (53.7) 
220.9 (53.1) 
196.1 (59.5) 
 
213.6 (63.2) 
206.5 (52.5) 
 
239.2 (51.8) 
207.0 (52.9) 
 
245.8 (57.5) 
206.8 (52.5) 
 
199.6 to 213.8 
203.0 to 220.1 
 
202.7 to 218.9 
212.0 to 271.2 
193.4 to 237.9 
193.2 to 208.8 
 
205.2 to 218.5 
177.1 to 209.3 
189.7 to 213.5 
 
201.2 to 213.4 
205.8 to 235.9 
177.8 to 214.4 
 
196.2 to 231.1 
200.7 to 212.4 
 
210.5 to 267.9 
201.2 to 212.8 
 
204.7 to 286.9 
201.0 to 212.6 
 
    
0.39   
 
 
 
 
< 0.04   
 
 
 
0.09  
 
 
 
0.17    
 
 
0.38 
 
 
< 0.03 
 
 
< 0.03  
 * Spontaneous vaginal delivery
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Table 2 Relationship between zones from Kramer's scale, and serum bilirubin levels 
 N Mean (SD) 
 
Minimum 
 
Maximum 
95% Confidence 
Interval 
Head and neck 54 183.39 (52.06)  74 318 169.18 to 197.60 
Upper trunk 110 197.78 (47.31) 62 325 188.84 to 206.72 
Lower trunk, thighs 87 220.77 (54.64) 107 340 209.12 to 232.42 
Arms, legs below knees 79 226.30 (50.24) 96 329 215.05 to 237.56 
Hands, feet 34 207.26 (55.41) 101 332 187.93 to 226.60 
Total 364 207.31(54.48) 20 340 201.71 to 212.91 
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Table 3 Number of infants definitely requiring phototherapy according to the reference 
standard11 using zones from Kramer’s scale  
Age (hrs)           Dermal zone when 
                           test ordered 
Serum bilirubin level 
 
Total 
 
  < 260 260-310 311-340 > 340   
< 48   Head and neck 15 0 0 0 15
    Upper trunk 28 1 0 0 29
    Lower trunk, thighs 23 1 0 0 24
    Arms, legs below 
knees 
18 1 0 0 19
    Hands, feet 7 0 0 0 7
  Total 91 3* 0 0 94
49-72   Head and neck 17 2 0 0 19
    Upper trunk 48 5 1 0 54
    Lower trunk, thighs 26 3 6 0 35
    Arms, legs below 
knees 
28 6 2 0 36
    Hands, feet 13 2 0 0 15
  Total 132 18 9* 0 159
> 72 
hrs 
 Head and neck 
19 0 1 0 20
    Upper trunk 23 3 1 0 27
    Lower trunk, thighs 17 8 3 0 28
    Arms, legs below 
knees 
13 10 1 0 24
    Hands, feet 8 3 1 0 12
  Total 80 24 7 0 111
* Indicates number of infants where phototherapy is required 
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Table 4. Number of infants where phototherapy may be considered according to the 
reference standard11  using zones from  Kramer's scale  
Age 
(hrs) 
Dermal zone when  
test ordered 
Serum bilirubin levels  
 
Total 
 
  
 
< 170 
 
171-260 
 
261-290 
 
> 290 
   
< 48  Head and neck 13 2 0   15
    Upper trunk 10 18 1   29
    Lower trunk, thighs 8 15 1   24
    Arms, legs below 
knees 
4 14 1   19
    Hands, feet 1 6 0   7
  Total 36 55* 3*   94
49-72  Head and neck 8 9 1 1 19
    Upper trunk 16 32 4 2 54
    Lower trunk, thighs 4 22 3 6 35
    Arms, legs below 
knees 
7 21 4 4 36
    Hands, feet 6 7 2 0 15
  Total 41 91 14* 13* 159
> 73  Head and neck 4 15 0 1 20
    Upper trunk 3 20 2 2 27
    Lower trunk, thighs 2 15 7 4 28
    Arms, legs below 
knees 
1 12 7 4 24
    Hands, feet 1 7 1 3* 12
  Total 11 69 17 14 111
* Indicates number of infants where phototherapy may be considered 
